InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key milestones the company had reached, including the acquisition of BayMedica, which Adams said positioned InMed as a clear leader in rare cannabinoid manufacturing. Adams…